Senior Vice President and Chief Medical Officer, Chemgenex
| Role | Organisation | Sources |
|---|---|---|
| Senior Vice President and Chief Medical Officer | Chemgenex | GBS Ventures (2 Jun 2009), GBS Ventures (8 Oct 2007) |
Stories naming Dr Adam R. Craig. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ChemGenex reported Phase 2/3 trial results for omacetaxine in resistant CML patients at ASCO, with investigators suggesting it could become the first workable therapy for T315I-mutant patients; regulatory filing targeted for Q3.
ChemGenex Pharmaceuticals has hired oncology drug developer Dr Adam Craig as its chief medical officer, its third senior clinical appointment lately, as it prepares its cancer drug omacetaxine for a regulatory filing.